These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 11593107)

  • 41. Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension.
    Koh KK; Han SH; Chung WJ; Ahn JY; Jin DK; Kim HS; Park GS; Kang WC; Ahn TH; Shin EK
    Am J Cardiol; 2004 Jun; 93(11):1432-5, A10. PubMed ID: 15165934
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The value of irbesartan in the management of hypertension.
    Bramlage P; Durand-Zaleski I; Desai N; Pirk O; Hacker C
    Expert Opin Pharmacother; 2009 Aug; 10(11):1817-31. PubMed ID: 19601700
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differences in pharmacology and their translation into differences in clinical efficacy--a comparison of the renin angiotensin blocking agents irbesartan and losartan.
    Bramlage P; Schindler C
    Expert Opin Pharmacother; 2010 Mar; 11(4):521-35. PubMed ID: 20030566
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
    Lewis EJ; Hunsicker LG; Clarke WR; Berl T; Pohl MA; Lewis JB; Ritz E; Atkins RC; Rohde R; Raz I;
    N Engl J Med; 2001 Sep; 345(12):851-60. PubMed ID: 11565517
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.
    Rodby RA; Rohde RD; Clarke WR; Hunsicker LG; Anzalone DA; Atkins RC; Ritz E; Lewis EJ
    Nephrol Dial Transplant; 2000 Apr; 15(4):487-97. PubMed ID: 10727543
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Angiotensin Receptor Blockers Effect on Serum Uric Acid-A Class Effect?
    Sutton Burke EM; Kelly TC; Shoales LA; Nagel AK
    J Pharm Pract; 2020 Dec; 33(6):874-881. PubMed ID: 31390929
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Losartan vs. amlodipine treatment in elderly oncologic hypertensive patients: a randomized clinical trial.
    Motta M; Russo C; Vacante M; Liardo RL; Reitano F; Cammalleri L; Costanzo M; Benfatto G; Frazzetto P; Mondati E; Malaguarnera M; Pennisi G
    Arch Gerontol Geriatr; 2011; 53(1):60-3. PubMed ID: 20569998
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study.
    Palatini P; Jung W; Shlyakhto E; Botha J; Bush C; Keefe DL
    J Hum Hypertens; 2010 Feb; 24(2):93-103. PubMed ID: 19458624
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The clinical efficacy and tolerability of the angiotensin II-receptor antagonist losartan in Japanese patients with hypertension.
    Ogihara T; Yoshinaga K
    Blood Press Suppl; 1996; 2():78-81. PubMed ID: 8913545
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Controlling blood pressure throughout the day: issues in testing a new anti-hypertensive agent.
    Weber MA; Neutel JM; Smith DH
    J Hum Hypertens; 1995 Nov; 9 Suppl 5():S29-35. PubMed ID: 8583478
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus.
    Mugellini A; Preti P; Zoppi A; Corradi L; Fogari E; Derosa G; Fogari R
    J Hum Hypertens; 2004 Oct; 18(10):687-91. PubMed ID: 15071488
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment with irbesartan or atenolol improves endothelial function in essential hypertension.
    von zur Mühlen B; Kahan T; Hägg A; Millgård J; Lind L
    J Hypertens; 2001 Oct; 19(10):1813-8. PubMed ID: 11593101
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy, safety and tolerability of valsartan 80 mg compared to irbesartan 150 mg in hypertensive patients on long-term hemodialysis (VALID study).
    Leidig M; Bambauer R; Kirchertz EJ; Szabã T; Handrock R; Leinung D; Baier M; Schmieder RE
    Clin Nephrol; 2008 Jun; 69(6):425-32. PubMed ID: 18538118
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Irbesartan effects on renal function in patients with renal impairment and hypertension: a drug-withdrawal study.
    De Rosa ML; de Cristofaro A; Rossi M; Baiano A; Cardace P; Albanese L; Vigorito C
    J Cardiovasc Pharmacol; 2001 Sep; 38(3):482-9. PubMed ID: 11486253
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients.
    Krum H; Nolly H; Workman D; He W; Roniker B; Krause S; Fakouhi K
    Hypertension; 2002 Aug; 40(2):117-23. PubMed ID: 12154100
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist, in the treatment of hypertension.
    Mallion JM; Goldberg AI
    Blood Press Suppl; 1996; 2():82-6. PubMed ID: 8913546
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of an angiotensin II receptor antagonist in managing hyperaldosteronism.
    Stokes GS; Monaghan JC; Ryan M; Woodward M
    J Hypertens; 2001 Jun; 19(6):1161-5. PubMed ID: 11403366
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Irbesartan substitution for valsartan or losartan in treating hypertension.
    Graham MR; Allcock NM
    Ann Pharmacother; 2002 Dec; 36(12):1840-4. PubMed ID: 12452741
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism.
    Takahashi S; Moriwaki Y; Yamamoto T; Tsutsumi Z; Ka T; Fukuchi M
    Ann Rheum Dis; 2003 Jun; 62(6):572-5. PubMed ID: 12759298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.